• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    ReCode Therapeutics Appoints Shehnaaz Suliman, M.D., MBA, M.Phil., as Chief Executive Officer

    1/10/22 8:00:00 AM ET
    $RARE
    $TXG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $RARE alert in real time by email

    Dr. Suliman brings over 25 years of drug development, deal-making and company building expertise as ReCode continues advancing its pipeline of novel genetic medicines using its powerful selective organ targeting (SORT) LNP delivery platform

    ReCode Therapeutics (the "Company"), a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary LNP delivery platform, today announced the appointment of Shehnaaz Suliman, M.D., MBA, M.Phil., as chief executive officer and as a member of the board of directors effective today. Former CEO, David Lockhart, Ph.D., will transition to the role of chief scientific officer and will remain president and a member of the board of directors.

    "I am excited about furthering the development of transformative therapeutics for patients with ReCode's first-in-class LNP platform and promising genetic medicines pipeline," said Shehnaaz Suliman, M.D., MBA, M.Phil., chief executive officer, ReCode Therapeutics. "There is vast untapped potential in RNA medicines and the delivery of genetic payloads to modify and potentially remedy a wide variety of life-limiting diseases. I am humbled to lead ReCode into its next stage of growth and look forward to partnering with Dr. Lockhart and the team to continue to execute our mission to develop a new generation of first-in-class mRNA-based and gene editing therapies for patients."

    "Dr. Suliman has an exceptional track record of building and transforming small and large life science companies into leading biotechnology companies. Her impressive business acumen, ability to advance assets through the clinic and competency in deal-making make her an outstanding fit for CEO as we enter our next chapter of growth," said David Lockhart, Ph.D., president and chief scientific officer, ReCode Therapeutics. "I am personally very excited to partner with Dr. Suliman, and we are invigorated by her arrival and look forward to leveraging her expertise as we advance our powerful LNP platform and robust pipeline of treatments for patients with life-limiting genetic diseases."

    Dr. Suliman is a physician, drug developer and dealmaker with over 25 years of experience building and transforming small and large biopharmaceutical companies. She most recently served as president and chief operating officer of Alector, a leading immuno-neurology and immuno-oncology company where she played a critical role growing, scaling, raising capital and advancing a late-stage development pipeline. Prior to Alector, she served as senior vice president, corporate development and strategy at Theravance Biopharma from 2017 to 2019, where she helped deliver a $1B profit sharing partnership with Janssen for the company's lead JAK inhibitor program. Prior to Theravance, Dr. Suliman was vice president and global head, immunology, infectious diseases and specialty care at Roche from 2015 to 2017. Dr. Suliman worked for Genentech as a group leader and project team leader in the R&D Portfolio Management and Operations Group from 2010 to 2015, where she oversaw an early development portfolio of more than 30 programs across multiple therapeutic areas. She held various management roles of increasing responsibility at Gilead Sciences, Inc. between 2005 and 2010 and played a significant role in forward-integrating Gilead into new therapeutic areas through M&A. Prior to Gilead, Dr. Suliman was an investment banker with Lehman Brothers and Petkevich & Partners, advising numerous public and private companies on buy- and sell-side transactions. She was named as one of the 2017 Fiercest Women in Life Sciences and as one of the National Diversity Council's Power 50 in 2021 (Most Influential Women in Business). Dr. Suliman serves as an independent director on the Board of Directors of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and 10x Genomics (NASDAQ:TXG). Dr. Suliman received her M.D. (MB, ChB) from the University of Cape Town Medical School, South Africa, and holds an MBA, with distinction, and M.Phil. degrees from Oxford University, where she was a Rhodes Scholar.

    About ReCode Therapeutics

    ReCode Therapeutics is an integrated genetic medicines company developing disease-modifying therapeutics using its powerful LNP delivery technology to target organs and tissues beyond the liver. The Company's pipeline includes lead programs for patients with life-limiting genetic respiratory diseases, including cystic fibrosis and primary ciliary dyskinesia. The Company is leveraging its proprietary LNP platform and nucleic acid technologies and utilizing systemic and direct delivery for mRNA-mediated replacement and gene editing/correction in target cells, including stem cells. For more information, visit www.recodetx.com and follow us on Twitter @ReCodeTx and LinkedIn.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20220110005163/en/

    Get the next $RARE alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RARE
    $TXG

    CompanyDatePrice TargetRatingAnalyst
    10x Genomics Inc.
    $TXG
    9/11/2025$15.00Neutral
    Piper Sandler
    Ultragenyx Pharmaceutical Inc.
    $RARE
    7/28/2025$80.00Buy
    H.C. Wainwright
    Ultragenyx Pharmaceutical Inc.
    $RARE
    5/28/2025Outperform
    William Blair
    10x Genomics Inc.
    $TXG
    2/13/2025$25.00 → $12.00Outperform → Market Perform
    Leerink Partners
    10x Genomics Inc.
    $TXG
    9/3/2024$35.00Outperform
    Leerink Partners
    10x Genomics Inc.
    $TXG
    7/22/2024$24.00Hold → Buy
    Jefferies
    10x Genomics Inc.
    $TXG
    7/18/2024$40.00 → $20.00Overweight → Neutral
    JP Morgan
    10x Genomics Inc.
    $TXG
    7/10/2024$55.00 → $25.00Buy → Hold
    Deutsche Bank
    More analyst ratings

    $RARE
    $TXG
    SEC Filings

    View All

    Ultragenyx Pharmaceutical Inc. filed SEC Form 8-K: Other Events

    8-K - Ultragenyx Pharmaceutical Inc. (0001515673) (Filer)

    9/8/25 4:15:17 PM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by 10x Genomics Inc.

    144 - 10x Genomics, Inc. (0001770787) (Subject)

    8/22/25 4:26:28 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Ultragenyx Pharmaceutical Inc. filed SEC Form 8-K: Other Events

    8-K - Ultragenyx Pharmaceutical Inc. (0001515673) (Filer)

    8/18/25 8:30:28 AM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RARE
    $TXG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President

    NOVATO, Calif., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) today announced the appointment of Eric Olson as chief business officer (CBO) and executive vice president effective September 22, 2025, following the planned retirement of Thomas Kassberg. Mr. Olson will be responsible for leading the company's business development, corporate development and alliance management functions. "We thank Tom for his 14 years of impactful contributions to Ultragenyx, including transformative business deals that helped build the largest clinical pipeline in rare disease; expanded our reach to patients with fatty acid oxidation diseases, X-linked hypophosphatemia, o

    9/30/25 4:05:00 PM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    NOVATO, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 48,561 restricted stock units of the company's common stock to 17 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company's board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of September 16, 2025, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c

    9/19/25 4:30:00 PM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CLISEQ, 10X Genomics and Weizmann Institute to Investigate Single Cell Applications in Hematology Clinical Diagnostics

    Worldwide clinical PERIBLOOD™ trial by the Weizmann Institute to evaluate single cell RNA sequencing from blood as a Non-Invasive Path for Blood Disorder Diagnosis, complementing bone marrow procedures PLEASANTON, Calif. and REHOVOT, Israel, Sept. 9, 2025 /PRNewswire/ -- CLISEQ Ltd., a translational diagnostics company spun out of Yeda, the commercial arm of the Weizmann Institute of Science, today announced a translational research collaboration with 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology and the Weizmann Institute. Together, the organizations are launching a multi-year, international clinical research study to investigate the use of peripheral single c

    9/9/25 9:00:00 AM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RARE
    $TXG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Chief Accounting Officer Huizenga Theodore Alan sold $1,867 worth of shares (64 units at $29.17), decreasing direct ownership by 0.13% to 50,242 units (SEC Form 4)

    4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)

    9/19/25 6:23:43 PM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Saxonov Serge gifted 900 shares, decreasing direct ownership by 0.09% to 1,034,817 units (SEC Form 4)

    4 - 10x Genomics, Inc. (0001770787) (Issuer)

    9/16/25 4:37:26 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    EVP and Chief Legal Officer Parschauer Karah Herdman sold $76,366 worth of shares (2,450 units at $31.17), decreasing direct ownership by 3% to 73,271 units (SEC Form 4)

    4 - Ultragenyx Pharmaceutical Inc. (0001515673) (Issuer)

    9/12/25 4:11:58 PM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RARE
    $TXG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mateo Alan bought $445,572 worth of shares (40,000 units at $11.14), increasing direct ownership by 184% to 61,691 units (SEC Form 4)

    4 - 10x Genomics, Inc. (0001770787) (Issuer)

    2/25/25 5:22:04 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RARE
    $TXG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on 10x Genomics with a new price target

    Piper Sandler initiated coverage of 10x Genomics with a rating of Neutral and set a new price target of $15.00

    9/11/25 8:40:00 AM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    H.C. Wainwright resumed coverage on Ultragenyx Pharma with a new price target

    H.C. Wainwright resumed coverage of Ultragenyx Pharma with a rating of Buy and set a new price target of $80.00

    7/28/25 9:00:36 AM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    William Blair initiated coverage on Ultragenyx Pharma

    William Blair initiated coverage of Ultragenyx Pharma with a rating of Outperform

    5/28/25 9:09:46 AM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RARE
    $TXG
    Leadership Updates

    Live Leadership Updates

    View All

    Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President

    NOVATO, Calif., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) today announced the appointment of Eric Olson as chief business officer (CBO) and executive vice president effective September 22, 2025, following the planned retirement of Thomas Kassberg. Mr. Olson will be responsible for leading the company's business development, corporate development and alliance management functions. "We thank Tom for his 14 years of impactful contributions to Ultragenyx, including transformative business deals that helped build the largest clinical pipeline in rare disease; expanded our reach to patients with fatty acid oxidation diseases, X-linked hypophosphatemia, o

    9/30/25 4:05:00 PM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    10x Genomics Announces Senior Leadership Changes

    PLEASANTON, Calif., Aug. 8, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced today several changes to its executive team. Mennah Moustafa has been named Chief Commercial Officer, effective August 1. In this role, Moustafa will be responsible for driving commercial strategy and execution and leading the company's sales, support and marketing functions.Justin McAnear, Chief Financial Officer, will resign from the company effective August 30, to join a private company.Adam Taich has been appointed Chief Financial Officer

    8/8/24 4:05:00 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Ultragenyx Appoints Howard Horn as Chief Financial Officer and Executive Vice President, Corporate Strategy

    NOVATO, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today announced that it has appointed Howard Horn as executive vice president and chief financial officer (CFO) effective October 16, 2023. Mr. Horn will be responsible for leading the finance, accounting, corporate strategy and investor relations functions. "Howard is joining Ultragenyx and its leadership team during a pivotal period as our robust late-stage pipeline is maturing and we are preparing for the next phase of company growth," said Emil D. Kakkis, M.D.,

    7/12/23 8:00:00 AM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RARE
    $TXG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Ultragenyx Pharmaceutical Inc.

    SC 13G/A - Ultragenyx Pharmaceutical Inc. (0001515673) (Subject)

    11/14/24 6:42:29 AM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by 10x Genomics Inc.

    SC 13G - 10x Genomics, Inc. (0001770787) (Subject)

    11/8/24 2:46:37 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by 10x Genomics Inc.

    SC 13G - 10x Genomics, Inc. (0001770787) (Subject)

    11/5/24 6:07:26 AM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RARE
    $TXG
    Financials

    Live finance-specific insights

    View All

    10x Genomics Reports Second Quarter 2025 Financial Results

    PLEASANTON, Calif., Aug. 7, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the second quarter ended June 30, 2025. Recent Updates Revenue was $172.9 million for the second quarter. Excluding $27.3 million related to a patent litigation settlement, revenue was $145.6 million.Ended the second quarter with cash and cash equivalents and marketable securities of $447.3 million, representing a $20 million increase over the prior quarter.Entered into a definitive agreement to acquire Scale Biosc

    8/7/25 4:05:00 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Ultragenyx Reports Second Quarter 2025 Financial Results and Corporate Update

    Second quarter total revenue of $166 million,Crysvita® revenue of $120 million and Dojolvi® revenue of $23 million Reaffirm 2025 Revenue Guidance: Total revenue between $640 million to $670 million, Crysvita revenue of $460 million to $480 million, and Dojolvi revenue of $90 million to $100 million UX143 for osteogenesis imperfecta Phase 3 data from Orbit and Cosmic studies expected around the end of the year GTX-102 for Angelman syndrome received Breakthrough Therapy Designation from FDA;Phase 3 Aspire study fully enrolled NOVATO, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercia

    8/5/25 4:01:00 PM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ultragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate Update

    NOVATO, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Tuesday, August 5, 2025, to discuss its financial results and corporate update for the quarter ending June 30, 2025. The live and replayed webcast of the call will be available through the company's website at https://ir.ultragenyx.com/events-presentations. The replay of the call will be available for three months. About Ultragenyx Pharmaceutical Inc.Ultragenyx is a biopharmace

    7/30/25 8:30:00 AM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care